Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals, Inc (ADIL)
US:NASDAQ Investor Relations:
adialpharma.com
Company Research
Source: GlobeNewswire
GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that for the last 10 consecutive business days, from February 6 through February 20, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or greater. The Company has now successfully resolved its Nasdaq compliance issue and Nasdaq has advised that the matter is now closed. Cary Claiborne, President and Chief Executive Officer of Adial, commented, “Regaining compliance represents an important milestone as we advance AD04 toward the pivotal Phase 3 program. Over the past sever
Show less
Read more
Impact Snapshot
Event Time:
ADIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADIL alerts
High impacting Adial Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
ADIL
News
- Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to OneGlobeNewswire
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswire
- Adial Pharmaceuticals (NASDAQ:ADIL) was given a new $8.00 price target on by analysts at UBS Group AG.MarketBeat
- Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04GlobeNewswire
ADIL
Sec Filings
- 2/24/26 - Form 8-K
- 2/18/26 - Form SCHEDULE
- 2/4/26 - Form 8-K
- ADIL's page on the SEC website